KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Other Accumulated Expenses (2018 - 2024)

Historic Other Accumulated Expenses for Adaptive Biotechnologies (ADPT) over the last 7 years, with Q4 2024 value amounting to $830000.0.

  • Adaptive Biotechnologies' Other Accumulated Expenses rose 878.11% to $830000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $830000.0, marking a year-over-year increase of 878.11%. This contributed to the annual value of $830000.0 for FY2024, which is 878.11% up from last year.
  • Adaptive Biotechnologies' Other Accumulated Expenses amounted to $830000.0 in Q4 2024, which was up 878.11% from $763000.0 recorded in Q4 2023.
  • In the past 5 years, Adaptive Biotechnologies' Other Accumulated Expenses registered a high of $1.9 million during Q4 2020, and its lowest value of $763000.0 during Q4 2023.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $1.0 million (2021), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Other Accumulated Expenses skyrocketed by 23830.94% in 2020, and later plummeted by 5389.73% in 2023.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Other Accumulated Expenses stood at $1.9 million in 2020, then tumbled by 44.5% to $1.0 million in 2021, then skyrocketed by 58.52% to $1.7 million in 2022, then tumbled by 53.9% to $763000.0 in 2023, then rose by 8.78% to $830000.0 in 2024.
  • Its Other Accumulated Expenses stands at $830000.0 for Q4 2024, versus $763000.0 for Q4 2023 and $1.7 million for Q4 2022.